Skip to content
LATEST
Health

Merck’s Sac-TMT improves survival in Phase 3 gastroesophageal cancer trial

The investigational TROP2-directed antibody-drug conjugate missed progression-free survival, leaving regulators to assess an overall-survival result without…

Merck's Sac-TMT improves survival in Phase 3 gastroesophageal cancer trial

Merck said in a Nov. 20 press release that its 473-patient Phase 3 TroFuse-015 trial met its primary overall-survival endpoint for sacituzumab tirumotecan, or sac-TMT.

The randomized, open-label global trial tested the investigational drug in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma after two or more prior systemic therapies, a late-line setting with limited options.

Merck said sac-TMT improved overall survival, meaning how long patients lived, compared with treatment of physician’s choice. The comparison options were trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel.

"Sac-TMT is the first TROP2 ADC to improve OS in a global Phase 3 study in advanced gastroesophageal adenocarcinoma compared to TPC, demonstrating its potential in a particularly challenging disease setting,” said Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories.

Sac-TMT is an antibody-drug conjugate, a cancer therapy designed to deliver a cell-killing payload to cells expressing a target. In this case, the target is TROP2, a protein Merck said is overexpressed on tumor cells compared with healthy cells in many common cancers.

The trial did not meet its secondary endpoint of progression-free survival, which measures how long patients live without the disease worsening, as assessed by blinded independent central review. Merck also said objective response rate favored sac-TMT, but that result was not formally tested under the prespecified analysis plan.

The press release did not provide median overall survival, hazard ratios, confidence intervals, p-values or absolute differences between sac-TMT and physician’s-choice treatment. Those details are needed to judge the size and clinical relevance of the benefit.

Merck said the safety profile matched earlier sac-TMT studies and that no new safety signals were observed. The company did not include detailed adverse-event rates in the announcement.

TroFuse-015 is the second positive Phase 3 readout from Merck’s TroFuse program. The company said the program includes 18 ongoing global Phase 3 trials across multiple tumor types and more than 15,000 patients worldwide.

Sac-TMT was developed by Kelun-Biotech. Under an exclusive license and collaboration agreement, Kelun-Biotech granted Merck rights to develop, manufacture and commercialize the drug outside Greater China.

The study cannot show from the released information how much longer patients lived, whether specific subgroups benefited more, or whether the survival result will support approval in a particular market. Merck said the data will be presented at an upcoming medical meeting and shared with regulatory authorities.

Source: company press release, Merck, Nov. 20, 2026.

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news